


# *Silent Genomes*

## *IBVL Resource Document*

---

*Version 1.2*  
*March 26, 2026*



Written in collaboration with the Silent Genomes Indigenous Rare  
Disease Diagnosis (S-GIRDD) Steering Committee and SG-IBVL  
Governance Committee members

## TABLE OF CONTENTS

### 3 **SUMMARY**

- 3            Silent Genomes Project
- 4            Silent Genomes Indigenous Rare Disease Diagnosis (S-GIRDD) Steering  
              Committee
- 4            Silent Genomes Indigenous Background Variant Library (SG-IBVL)  
              Governance Committee

### 5 **INDIGENOUS BACKGROUND VARIANT LIBRARY**

- 5            Intention of the IBVL
- 5            Terms of Intended Use
- 6            Development
- 6                       Participants in the IBVL
- 6                       Sample Management
- 6                       Sample Processing / Sequencing
- 6                       Confidentiality of Patients' and Communities' Identities
- 7            Governance
- 7            IBVL Model
- 7                       Benefits
- 7                       Security
- 8                       Access Model
- 8                       Registered Release of Variants
- 9                       Registrant Accountability

### 10 **APPENDICES**

- 10            Definitions
- 10            CARE Principles for Indigenous Data Governance
- 11            The First Nations Principles of Ownership, Control, Access, and  
              Possession
- 12            IBVL Links
- 12            IBVL Video
- 13            Funding Information

## SUMMARY

### Silent Genomes Project

[The Silent Genomes Project \(SGP\)](#) is a national research initiative aimed at increasing access to genomic testing technologies and improving diagnostic outcomes for Indigenous Peoples with genetic diseases. The SGP is supported by the Assembly of First Nations, the Métis National Council, and Inuit Tapiriit Kanatami. The SGP has partnered with the First Nations Canadian Alliance for Healthy Hearts and Minds (CAHHM; 'Alliance Study') and has been guided by the International Indigenous Genomics Advisory Committee (IIGAC). The SGP is also guided by Indigenous community members, scholars and allies who we are honored to work with and alongside and is dedicated to making decisions that best serve First Nations, Inuit, and Métis people.

The project has entered its extension phase under the new name "Silent Genomes: Building a sustainable path to genetic/genomic care for Indigenous People of Canada and beyond," reflecting its evolving focus and long-term goals. This phase encompasses three overlapping activities with Indigenous engagement, governance, and capacity building as cross-cutting themes integrated throughout all activities.

The extended Silent Genomes Project focuses on the following key activities:

**Integrating Indigenous-led governance, community engagement, community education, and student capacity building** across all activities.

**Rare Insights: Advancing care for rare genetic diseases affecting Indigenous families.** This activity includes providing evidence for putative disease variants, identifying genetic causes for conditions with community impact, clinically validating the IBVL for rare diseases and system-based genetic testing panels, and translating genetic discoveries into clinical care for affected communities.

**Expanding and sustaining the Indigenous Background Variant Library (IBVL).** Efforts include enhancing its quality, increasing First Nations community participation, engaging with Métis and Inuit leadership about inclusion, developing ethical processes for individual Indigenous participation, and fostering international partnerships to strengthen Indigenous genomic reference data and equity.

**Equity, social, and economic implications of genomic diagnosis and the IBVL.** This includes analyzing economic impacts within Indigenous health and well-being contexts, understanding preferences for diagnostic testing, developing inclusive survey methods, creating data-sharing strategies for sustainable research pipelines, and integrating clinical data to assess healthcare equity for Indigenous children in British Columbia.

This document serves as a resource for those who will be accessing the IBVL. The development and implementation of an IBVL containing reference genomic data from Indigenous participants are key to improving access to the benefits of genomic diagnosis.

## **The Silent Genomes Indigenous Rare Disease Diagnosis (S-GIRDD) Steering Committee (*inactive*)**

[The S-GIRDD Steering Committee](#) was established to provide cultural oversight and strategic advice in support of the collaborative creation, implementation, and utilization of the IBVL, including respectful, culturally safe policies regarding access to data and clinical diagnoses [and related research]. Over a period of four years (2020-2025), the committee established the mechanism for variant release for clinical diagnosis, criteria for the consideration of research, and processes for research and manuscript review.

With the release of the IBVL, the S-GIRDD Steering Committee has now transitioned to the Silent Genomes Indigenous Background Variant Library Governance Committee, which will sustainably provide oversight of the IBVL (see below).

## **The Silent Genomes Indigenous Background Variant Library (SG-IBVL) Governance Committee**

[The SG-IBVL Governance Committee](#) is established to provide cultural oversight and strategic advice and decisions in support of the collaborative expansion and utilization of the IBVL including respectful, culturally safe policies regarding access to data for clinical diagnoses and related research, while engaging future generations of Indigenous scholars and community members.

The Committee is Indigenous-led and Indigenous-operationalized, including Knowledge Carriers/Elders, members from First Nations, Métis, and Inuit communities, as well as those with connections to genetic conditions or affiliations with the Canadian Alliance for Healthy Hearts and Minds, Indigenous scholars, youth, and emerging leaders.

The SG-IBVL Governance Committee works alongside the Silent Genomes team in consultation and partnership with Indigenous communities and leaders as the IBVL expands to ensure that participating Indigenous individuals, families, and communities have their genomic data securely protected, used ethically within the scope of consent, governed by Indigenous data sovereignty principles, and safeguarded with transparency, accountability, and culturally appropriate oversight throughout the IBVL's existence and beyond.

Roles, responsibilities, and other pertinent information is found in the [Terms of Reference](#).

## INDIGENOUS BACKGROUND VARIANT LIBRARY

### Intention of the IBVL

The **Indigenous Background Variant Library (IBVL)** is a database showing the frequency of each DNA variant found in a population of Indigenous people who have not been diagnosed with a severe genetic condition. Given the importance of background variant libraries (BVLs) in precision diagnosis, they have been created for many human populations, although mostly emphasizing individuals of European descent. It is crucial for as many populations as possible to be represented in BVLs, since variants not seen in one group of people may be more common in another. More information about DNA variants and BVLs is available [on the IBVL webpage](#).

To date, **Indigenous Peoples have had little representation in the BVLs** currently available. For example, people of European, Asian, African, and Ashkenazi Jewish backgrounds are represented in the most widely used background variant library, the [gnomAD](#) library, but very little data identified from Indigenous Peoples have been included.

The IBVL is a clinical tool designed to improve the diagnosis of genetic diseases. It is NOT a biobank containing human samples, nor will it be used to determine the level of Indigenous ancestry, geographical origins, or to challenge cultural beliefs. It will NOT be used for commercialization, patenting interests, or to provide 'direct to consumer' genetic test results to SGP participants. Its purpose is to provide access to the benefits of genomic medicine for Indigenous people.

**In conclusion, each population worldwide has genetic variants that are unique to them, which are not present in the DNA of other populations or may be found more or less frequently.** The lack of an IBVL means that genetic specialists and doctors lack information on which DNA variants are common and therefore are less likely to cause severe genetic disease in Indigenous Peoples. This gap makes diagnosing genetic conditions in Indigenous patients significantly more difficult and less efficient than many other patients because doctors cannot quickly rule out the common variants seen in the general population as they seek to find the real 'suspect' variants that cause a patient's rare disease. This unfortunately can result in delayed diagnosis, potentially less effective health management and treatment for patients, and ongoing stress for families due to unanswered questions. The SGP strives to address inequity in genetic diagnoses for Indigenous patients.

### Terms of intended use

By accessing the data, the user agrees to the following terms and conditions defined by the SG-IBVL Governance Committee:

- 1.Data is only to be used for purposes approved for by the SG-IBVL Governance Committee, including clinical diagnosis and approved health research.
- 2.Users should not copy or store multiple variant frequencies.

3. Access is only given to variant frequency. Underlying individual data will not be accessible, even upon request.
4. Users are limited to accessing 100 variant pages per 24hrs period. If users need to access more than the allotted variant pages per day, the user should contact us and detail the reasons for their extensive use of the database. The user's request will be reviewed and the decision will be communicated over email.
5. The data may not be used in an attempt to identify any individual in this or other studies.

## **Development**

All the SGP activities are integrated, and teams work in close collaboration. For example, as part of Activity 1 (First Nations, Inuit, and Métis Engagement, Governance and Capacity Building) of the Phase 1 SGP, an Indigenous Steering Committee (the S-GIRDD, see above) was established.

### **Participants in the IBVL**

Version 1.2 release of the IBVL was developed from 596 consented samples from some First Nation communities who are participating in the First Nations arm of the [Canadian Alliance for Healthy Hearts and Minds \(CAHHM\)](#) ['Alliance Study']. Extensive engagement took place (over a period of 5 years) to determine whether their samples stored for health research could be utilized for the IBVL. For those interested in proceeding, community approval was necessary for transfer as was appropriate Indigenous governance over the IBVL. The goal is to engage with other Indigenous communities, and perhaps patients and their families to allow expansion and robust genomic reference data coverage for all Indigenous people residing throughout all of Canada.

### **Sample Management**

There will be no biobanking as part of the IBVL. Samples will only be used to determine the DNA sequences required to build the IBVL.

### **Sample Processing / Sequencing**

Genomic DNA sequence data were generated at Canada's Michael Smith Genome Sciences Centre (GSC) at BC Cancer Agency. The genomic data was transferred to the BC Children's Hospital Research Institute for processing and variant frequencies are stored in the IBVL database.

### **Confidentiality of Patients' and Communities' Identities**

There is no personal or health information associated with the samples or data generated through genome sequencing. All samples used in the creation of the IBVL are anonymized before arrival at the GSC for genome sequencing. No personal or identifiable community information is included in the IBVL. A code for geographic region is included for the purpose of understanding geographical distribution of frequency of variants but that level of information would only be provided on an approved case-by-case basis. Variant information will be released to health professionals providing diagnoses to patients as per the access and registration requirements suggested by the S-GIRDD.

## **Governance**

It is acknowledged that the oversight of the IBVL is Indigenous. The S-GIRDD Steering Committee, and its successor, the SG-IBVL Governance Committee, were created to be Indigenous-led and Indigenous-operationalized with the support of the Silent Genomes team. Since the first phase of the IBVL utilized samples from consenting First Nations Canadian Alliance for Healthy Hearts and Minds (CAHHM) communities; Alliance representatives are key members of the SG-IBVL Governance Committee.

The committee provides strategic guidance, cultural safety oversight, and protocol development for the governance, use, communication, and future stewardship of data within the IBVL, while collaborating with Indigenous-led bodies and ensuring alignment with community values. Roles, responsibilities, and other pertinent information is found in the Terms of Reference.

The SG-IBVL Governance Committee will engage in the process of expanding the IBVL while respecting the preferences of our Indigenous partners for inclusion, and adhering to its governance framework.

## **IBVL Model**

### **Benefits**

The IBVL will benefit mainly those with genetic diseases (for example inherited heart disease, cancer, and severe genetic disease in children and adults) and their family members. Benefits are expected to include:

- Help healthcare providers understand the common DNA variants in Indigenous peoples in Canada and in their patients in particular [the consensus is the more common a variant is, the less likely it is to be a rare disease-causing variant];
- Indigenous peoples are helping Indigenous peoples for generations to come;
- Increased diagnoses of rare genetic diseases within the Indigenous community in Canada and potentially around the world;
- Increased equity and reduction of health disparities through more efficient and accurate diagnoses, which can lead to more accurate treatment plans, reduced wait time for diagnosis, and/or more information for patients and families.

Overall, the IBVL helps to address inequity and will provide better opportunities for genetic diagnoses aiming to improve overall medical care and well-being for families.

### **Security**

The IBVL only includes de-identified data, which means that no name or other identifier is associated with the genomic data. It is hosted at BC Children's Hospital Research Institute, where it is protected by multiple safeguards, including restricted access, monitoring of use, and other high-security features. All staff working with the IBVL are required to take relevant cultural safety training.

Data stored at the BC Children's Hospital Research Institute meets a high standard of security required for health information. This includes a firewall-protected network (with a commitment to continuous upgrades of the firewall), restricted access to data

to those with approved accounts, and computer server rooms with monitored access within buildings requiring pass-card entry. The SGP contracted an independent, external security audit of the BC Children's Hospital Research Institute, which confirmed the high standard of data protection.

The IBVL data is held within a database providing an audit trail, that means it records which users are accessing what data.

### Access model

Access to the IBVL is restricted and requires a registration step. This means that potential users will have to request access before using the IBVL and are prompted to fill out an online form before receiving approval.

Once a user submits all the required information, SGP staff will review and approve or decline the request. The approval is based on users with a need to access data in accordance with the IBVL guidelines. Once granted access, the user will further need to state their reasoning as to why they are accessing each variant within the IBVL. No approved user may access more than a small amount of data (100 queries) in a 24-hour time period, providing further protection to the information in the IBVL.

Those seeking to use the data in the IBVL for health research will be required to submit a research request that is reviewed, considered, and approved of by the SG-IBVL Governance Committee. Approved research data use will be supported by the Silent Genomes team and only accessible through their systems. Data will not be transferred to researchers.

### Registered Release of Variants

Before accessing variants, the interested user will fill out an online form. The form will ask for the user's information such as:

- Full name;
- Work email;
- Profession;
- Full name, email, and profession of those responsible for staff person accessing IBVL on that professional's behalf;
- Urgency of use;
  - ✧ Whether a user needs immediate access to the IBVL (e.g., a patient in a neonatal intensive care unit (NICU));
- How the IBVL will be used;
- Licensing number (if applicable);
- Institutional information;
  - ✧ Name;
  - ✧ Address;
  - ✧ Affiliation;
- Phone number;
- Username;
- Password.

Before submitting the required information, potential users must affirm that they have read and understood the purpose of the IBVL and include their initials to show

that they have read each point in the statement of context. In terms of the statement of context, the users need to agree that the IBVL's purpose is for diagnosis, and users will NOT use the IBVL for other reasons.

After they fill out that information, they wait to be approved by a staff professional.

Once registered, a user will sign in and again will need to review and agree to the statement of context and provide the reason for use. At this point, the search for a variant can be performed.

### **Registrant Accountability**

Users must understand and agree with each of the points within the statement of context. For questions on any of the points made in the statement of context, please feel free to reach out to the SGP at 1 (888) 853-8924. The user agrees to the statement of context by checking the boxes.

Each time someone uses the IBVL, they will be prompted to sign that they understand the statement of context which includes the following points:

- I agree that this IBVL has been developed specifically for the purpose of diagnosis.
- I agree that this information will not be used for other purposes, such as health research, without the review and approval of the SG-IBVL Governance Committee.
- I agree that this information will not be used for publication(s) without the review and approval of the SG-IBVL Governance Committee.
- I understand that this is a monitored registration, and the use of the database will be periodically reviewed.
- I have read and agree to the terms of the intended use stated in the IBVL resource document including respecting Indigenous data sovereignty (defined in the appendices of this document).
- I understand that failure to comply with this statement will result in access being revoked and other potential consequences.

As noted above, the IBVL database provides an audit trail – a record of when and which data is accessed by each user. The system is monitored for patterns that are inconsistent with appropriate use, and accounts will be immediately suspended if such behavior is detected.

If users abuse the IBVL, they will be held accountable through sanctions and legal actions by the British Columbia Provincial Health Services Authority (PHSA) as the Provincial Health Services Authority is legally responsible for the BC Children's Hospital Research Institute. This can result in rescinding access to the IBVL, reporting the behavior to professional organizations, employers, and/or communities, and other potential sanctions as appropriate.

## APPENDICES

These resources guide the SGP to ensure that we are consistent, respectful, and culturally safe when conducting research. For more principles, guidelines, and policies please refer to our [Best Practices webpage](#).

### Definitions

**Background Variant Library (BVL):** a list or collection of all the DNA variants in a group of people without severe genetic conditions, which helps to determine variants that are common or rare in the general population. More information about BVLs is available [on the IBVL webpage](#).

**Cultural Safety:** is an outcome based on respectful engagement that recognizes and strives to address power imbalances inherent in the health care system. It results in an environment free of racism and discrimination, where people feel safe when receiving health care. Definition from [Creating A Climate For Change](#) on the [FNHA website](#).

**Indigenous Data Sovereignty:** is at minimum, about the ownership and control of samples, records, information, and the data derived from it ([United Nations, 2007](#)), as defined by, and benefiting Indigenous peoples; and in particular, human and genetic resources ([Native BioData, 2021](#)). This is part of the inherent rights held by individuals and as citizens of distinct societies and nations, and includes but is not limited to the right to repatriate, maintain, protect and develop their biological and intellectual property ([British Columbia First Nations' Data Governance Initiative](#), n.d.).

### CARE Principles for Indigenous Data Governance

The CARE Principles were written in response to the FAIR Principles published in Scientific Data in 2016. Supporting open access to data, the FAIR Principles are defined by F: Findability, A: Accessibility, I: Interoperability, and R: Re-use of digital assets. Indigenous scholars ([International Indigenous Data Sovereignty Interest Group](#)) responded to the FAIR Principles with the slogan Be FAIR and CARE, CARE being defined by C: Collective Benefit, A: Authority to Control R: Responsibility E: Ethics ([CARE principles for Indigenous Data Governance](#)) reflecting concerns about secondary use of data and limited opportunities for benefit-sharing.

#### **C:** Collective Benefit

Research being done with Indigenous Peoples must benefit the community for equitable outcomes and contribute to well-being. This is done by governments actively supporting use and reuse of data, community engagement when planning, implementing, evaluating, and decision-making.

#### **A:** Authority to Control

Indigenous Peoples have the right and control over their own data for their own interests which is protected by their own Indigenous governance.

**R:** Responsibility

Those working with Indigenous data have the responsibility to maintain positive relationships with Indigenous Peoples which include providing resources for Indigenous language and world views and to enhance data literacy within Indigenous communities to expand capability and capacity.

**E:** Ethics

Indigenous People's rights should be the primary concern at all times in order to minimize harm and maximize benefit by addressing power imbalances and fighting for justice as well as take everything learned about data governance to improve ethics for future usage.

**The First Nations principles of Ownership, Control, Access, and Possession (commonly known as OCAP)**

Established in 1998 during a meeting of the National Steering Committee (NSC) of the First Nations and Inuit Regional Longitudinal Health Survey, [the First Nations Principles of Ownership, Control, Access, and Possession \(OCAP\)](#) were created to address the lack of laws or concepts to protect community rights, interests, and information. This means that First Nations have control over data collection processes, ownership of their data, and control over how their data can be used, stored, interpreted, and shared. OCAP is further defined as:

**O:** Ownership

Refers to when a community or group has ownership over their information or data just like it is their own personal data.

**C:** Control

First Nations can have the right to control all aspects of research from start to finish. This extends to having control over resources, review processes, planning processes, and information management.

**A:** Access

First Nations have access to information and data about themselves and their communities wherever it is stored. In addition, First Nations' Communities are also to manage and make decisions regarding the access of their information through standard or formal protocols.

**P:** Possession

While ownership refers to the relationship between people and their information, possession is more concrete. It is the mechanism by which ownership can be asserted and protected.

## IBVL links



IBVL direct link: <https://ibvl.bcchr.ca>

SG-IBVL Governance

Committee: <https://www.bcchr.ca/silent-genomes-project/our-team/sg-ibvl-governance-committee>

IBVL page on the SG

website: [https://www.bcchr.ca/silent-genomes-project/ibvl/ibvl\\_database](https://www.bcchr.ca/silent-genomes-project/ibvl/ibvl_database)

IBVL general information:

<https://www.bcchr.ca/silent-genomes-project/ibvl/general-information-ibvl-overview>

## IBVL Video

[The video](#) was developed in response to a request by one of the Alliance members to provide a short, easy-to-understand educational tool for community members. It was subsequently translated into French for one francophone Alliance community in Quebec.



## Funding information

The Silent Genomes Project has generously been supported by:

-  Genome BC
-  Genome Canada
-  Canadian Institutes for Health Research
-  Michael Smith Foundation for Health Research
-  BC Children's Hospital Research Institute
-  BC Children's Hospital Foundation
-  UBC Faculty of Medicine
-  Provincial Health Services Authority
-  LifeLabs (scholarship grants)
-  Illumina Inc. (in-kind)